Translate
Researchers at the Royal Free Hospital (RFH) are recruiting people to take part in a clinical trial to see if an investigational vaccine may be able to protect adults against the symptoms caused by the norovirus stomach bug.
Norovirus is one of the most common causes of stomach bugs in the UK and there is currently no vaccine to protect against the infection.
The Nova 301 Trial is a Phase 3 clinical trial. This is the last phase before an investigational vaccine can be made available for public use – after approval from the UK Medicines and Healthcare products Regulatory Agency.
People taking part in the trial must be 18 or over, in good health and should not currently have a chronic gastrointestinal disease (including irritable bowel syndrome, colitis, oesophageal reflux, or any other medical condition with regular vomiting or diarrhoea).
Participants will receive either the investigational vaccine or a placebo jab. The trial will last for up to 25 months, and participants must be willing to attend up to seven scheduled clinic visits over that time.
If you are interested in participating and want to find out more contact the Royal Free vaccine research team at rf.
Participants will be reimbursed for their trial-related time and expenses, for example, travel.
Fiona Burns, Professor of Epidemiology, at the RFH, said: “Norovirus spreads very easily from person to person, via food or contaminated surfaces, so once it takes hold, it can be very difficult to get rid of, especially in settings like care homes, hospitals and schools. While most people recover well in a few days, more vulnerable groups are more likely to need medical support or higher levels of care.”
The Nova 301 Trial is looking to recruit approximately 25,000 people globally.
